Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clarithromycin
Drug ID BADD_D00480
Description Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Indications and Usage An alternative medication for the treatment of acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity. Also for the treatment of pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, as well as respiratory tract infections including acute maxillary sinusitis, acute bacterial exacerbations of chronic bronchitis, mild to moderate community-acquired pneuomia, Legionnaires' disease, and pertussis. Other indications include treatment of uncomplicated skin or skin structure infections, helicobacter pylori infection, duodenal ulcer disease, bartonella infections, early Lyme disease, and encephalitis caused by Toxoplasma gondii (in HIV infected patients in conjunction with pyrimethamine). Clarithromycin may also decrease the incidence of cryptosporidiosis, prevent the occurence of α-hemolytic (viridans group) streptococcal endocarditis, as well as serve as a primary prevention for Mycobacterium avium complex (MAC) bacteremia or disseminated infections (in adults, adolescents, and children with advanced HIV infection).
Marketing Status approved
ATC Code J01FA09
DrugBank ID DB01211
KEGG ID D00276
MeSH ID D017291
PubChem ID 84029
TTD Drug ID D0Z1ZM
NDC Product Code 49452-2112; 46708-344; 46708-345; 57237-044; 61919-643; 71335-1493; 0781-6023; 65096-0100; 53002-7561; 65862-226; 0527-1932; 76420-051; 27241-064; 43063-530; 68071-5045; 68788-8480; 0527-1930; 57237-045; 60687-435; 63187-376; 63187-625; 71335-1567; 38779-1937; 63415-0018; 43063-942; 53002-7562; 62332-345; 68788-7933; 0527-1931; 62991-2687; 51655-668; 65862-225; 0781-6022; 43666-0001; 60592-429; 50090-5285; 67296-1072; 67296-1360; 68071-3116; 70518-2773; 71335-0017; 72189-299; 0781-1961; 15894-0026; 27241-065; 62135-615; 62135-616; 62332-344; 0591-2805; 59566-0123; 50090-5282; 50268-178; 50268-179; 64380-906; 67296-0464; 68071-2869; 0781-1962; 43063-752; 43063-823; 64380-905; 68788-7125; 0904-6872; 43781-0403; 51552-1566; 50090-1830
UNII H1250JIK0A
Synonyms Clarithromycin | 6-O-Methylerythromycin | TE-031 | TE 031 | TE031 | A-56268 | A 56268 | A56268 | Biaxin
Chemical Information
Molecular Formula C38H69NO13
CAS Registry Number 81103-11-9
SMILES CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N( C)C)O)(C)OC)C)C)O)(C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bronchitis chronic22.03.01.019--Not Available
Bronchospasm22.03.01.004; 10.01.03.0120.000335%
Bronchostenosis22.03.01.0200.000447%
Burning sensation17.02.06.001; 08.01.09.0290.001787%Not Available
Cardiac arrest02.03.04.0010.001787%
Cellulitis23.11.02.004; 11.02.01.001--Not Available
Cerebrovascular disorder17.08.02.002; 24.03.05.002--Not Available
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.0090.002680%Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.0110.005628%Not Available
Chills08.01.09.001; 15.05.03.0160.001340%
Choking22.12.03.0030.000670%Not Available
Choking sensation22.12.03.004; 19.01.02.0020.000670%Not Available
Cholecystitis09.03.01.0010.000447%
Cholestasis09.01.01.0010.001898%Not Available
Chromaturia20.02.01.0020.000782%
Circulatory collapse24.06.02.0010.000893%Not Available
Claustrophobia19.06.03.005--Not Available
Clostridium difficile colitis11.02.02.004; 07.19.01.004--Not Available
Coagulopathy01.01.02.0010.001117%Not Available
Cold sweat23.02.03.002; 08.01.03.024--Not Available
Colitis07.08.01.0010.001340%
Condition aggravated08.01.03.0040.004243%Not Available
Confusional state19.13.01.001; 17.02.03.0050.005404%
Conjunctivitis06.04.01.002; 11.01.06.012--
Constipation07.02.02.001--
Corneal deposits06.06.03.0020.000223%Not Available
Corneal opacity06.06.03.005--Not Available
Cough22.02.03.001--
Crohn's disease10.02.01.005; 07.08.01.0150.000893%Not Available
Crying17.02.05.013; 12.02.11.001; 08.01.03.005; 19.04.02.0020.000447%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 21 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene